Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary
- 2 December 2022
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (5) , 1030-1035
Abstract
The US Food and Drug Administration (FDA) Biosimilars Guidance describes how biosimilars may be approved based on clinical pharmacokinetic and pharmacodynamic (PD) biomarker data, without comparative clinical studies with efficacy end points. This type of clinical development program, however, has only been implemented for a small number of FDA‐approved biosimilar products over the last decade. To encourage the use of PD biomarkers in biosimilar development and approval, the Duke‐Margolis Center for Health Policy collaborated with the FDA to host a two‐day virtual public workshop entitled “Pharmacodynamic Biomarkers for Biosimilar Development and Approval” on September 20–21, 2021. The public workshop was a forum for global regulators, biopharmaceutical developers, and academic researchers to discuss the current and future role of PD biomarkers in improving the efficiency of biosimilar development and approval. The workshop objectives included: (i) discuss the current and potential future state of leveraging PD biomarkers for biosimilar development and approval; (ii) summarize the FDA's initiatives to advance biosimilar development; (iii) describe stakeholders' experience with PD biomarkers in biosimilar development; and (iv) explain research efforts to promote broader application of PD biomarkers in biosimilar development. This document summarizes presentations and panel discussions from each session of the two‐day September 2021 public workshop covering the application of PD biomarkers for biosimilar development.Keywords
This publication has 14 references indexed in Scilit:
- Academic oncology clinicians’ understanding of biosimilars and information needed before prescribingTherapeutic Advances in Medical Oncology, 2019
- Role of Modeling and Simulation in the Development of Novel and Biosimilar Therapeutic ProteinsJournal of Pharmaceutical Sciences, 2019
- Integrated omics: tools, advances and future approachesJournal of Molecular Endocrinology, 2019
- APK/PDAnalysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer PatientsClinical Pharmacology & Therapeutics, 2018
- The End of Phase 3 Clinical Trials in Biosimilars Development?BioDrugs, 2018
- Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G‐CSF in Breast Cancer PatientsClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacology: a Discipline at the Nexus Between Translational Science and Precision Medicine: Commentary on “Enhancing Value of Clinical Pharmacodynamics in Oncology Drug Development: An Alliance Between Quantitative Pharmacology and Translational Science”Clinical Pharmacology & Therapeutics, 2017
- A Dose–Response Meta-Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid ArthritisClinical Pharmacology & Therapeutics, 2011
- An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy SubjectsPharmaceutical Research, 2007
- Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena††Supported in part by Grant No. 24211 from the National Institute of General Medical Science, National Institutes of Health.Journal of Pharmaceutical Sciences, 1998